Elongation of aorta
Bicuspid aortic valve
Subaortic stenosis
Mitral valve prolapse with mitral regurgitation
Atrial septal defect
Patent ductus arteriosus
Tricuspid valve prolapse
Aortic dissection and aneurysm
Aneurysm of ductus arteriosus

Other reported symptoms
These symptoms were found in rare cases of Larsen syndrome. Cataracts
Cleft palate
Extra bones of wrist
Malocclusion
Microdontia and hypodontia
Complete agenesis of anus
Bifid uterus
Bifid tongue

Causes
Mutations in gene encoding filamin B
Filamins are cytoplasmic proteins that regulate the structure and activity of the cytoskeleton. These proteins serve as scaffolds on which intracellular signaling and protein trafficking are organized. Filamin B has been found to be expressed in human growth plate chondrocytes, which are especially important in vertebrae segmentation and skeleton morphogenesis. Genetic analysis of patients with Larsen syndrome has found the syndrome is caused by missense mutations in the gene that codes for filamin B. These mutations cause an accelerated rate of apoptosis in the epiphyseal growth plates of individuals with the mutation. The defects can cause short stature and other symptoms associated with Larsen syndrome. Localization
Genetic analysis has found that a gene linked to Larsen syndrome, LAR1, is strongly linked to chromosome 3p markers. The locus of this gene is found in a region defined distally by D3S1581 and proximally by D3S1600. This location can be mapped to chromosome region 3p21.1-14.1. Human type VII collagen gene is found within this region in chromosome region 3p21.1. It is reasonable to believe that the joint abnormalities and cardiac anomalies associated with Larsen syndrome are related to the fact that the human type VII collagen gene is found within the same chromosome region as the LAR1 gene.
Nicardipine (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the dihydropyridine class of calcium channel blockers. It is also used for Raynauds phenomenon. It is available in by mouth and intravenous formulations. It has been used in percutaneous coronary intervention. Nicardipine has been used as an alternative to sodium nitroprusside, especially because sodium nitroprusside is light sensitive and a fresh solution must be prepared. Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.It was patented in 1973 and approved for medical use in 1981. See also
Calcium channel blocker toxicity


== References ==